Impact Biomedical (NYSEAMERICAN:IBO) Posts Earnings Results

Impact Biomedical (NYSEAMERICAN:IBO) released its quarterly earnings results on Tuesday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.01 million for the quarter.

Impact Biomedical Price Performance

Shares of IBO stock remained flat at $0.63 during trading hours on Tuesday. 45,424 shares of the stock were exchanged, compared to its average volume of 3,028,599. Impact Biomedical has a twelve month low of $0.36 and a twelve month high of $1.95. The firm has a fifty day moving average of $0.61 and a two-hundred day moving average of $0.56. The firm has a market capitalization of $67.39 million, a price-to-earnings ratio of -0.16 and a beta of 3.15.

Insider Activity

In other news, Director Jason Grady sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $0.65, for a total transaction of $32,500.00. Following the sale, the director owned 250,182 shares in the company, valued at $162,618.30. The trade was a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 89.00% of the stock is owned by corporate insiders.

Impact Biomedical Company Profile

Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.